38 Fulton St W Ste 303
18 articles with Tetra Therapeutics
Tetra Discovery Partners, a clinical-stage biotechnology company, today announced the company’s name change to Tetra Therapeutics
Tetra Discovery Partners and Shionogi & Co., Ltd. Collaborate on BPN14770 Development and Commercialization
Deal Valued at Potential $160 Million plus Royalties, including $5 Million in Upfront Payments and $35 Million in Equity Investment
Intellectual Property Protection for Tetra Discovery Partners’ BPN14770 Boosted with Issuance of New U.S. Patent
The new patent, US 10,093,686, covers claims for the use such compounds in the treatment of mild cognitive impairment, Parkinson’s disease, stroke and ischemia.
Tetra Discovery Partners today announced the initiation of a Phase 2 study of BPN14770 as a potential treatment for Fragile X Syndrome
Tetra’s fragile X syndrome drug must demonstrate significant therapeutic benefits to secure market share, says GlobalData
BPN14770, which is being developed by Tetra Discovery Partners for the treatment of fragile X syndrome (FXS), was granted Orphan Drug Designation by the FDA in April 2018.
FDA Grants Orphan Drug Designation for Tetra Discovery Partners’ BPN14770 for the Treatment of Fragile X Syndrome
BPN14770 is a selective small molecule inhibitor of the phosphodiesterase type-4D (PDE4D) subtype.
Tetra Discovery Partners announced that the FDA had given its Investigational New Drug application the go-ahead for Fragile X Syndrome and potentially other autism spectrum disorders.
Tetra Discovery Partners Announces FDA Clearance of IND for Phase 2 Trial of BPN14770 in Fragile X Syndrome
Tetra Discovery Partners Inc. announced that the U.S. Food and Drug Administration has accepted the Investigational New Drug Application (IND) for BPN14770.
New Preclinical Research Suggests Utility of Tetra Discovery Partners' BPN14770 to Provide Therapeutic Benefit in Fragile X Syndrome
Microscopic analysis of neurons in the prefrontal cortex from the treated FXS mice showed an improvement in dendritic spine morphology.
Tetra Discovery Partners Research Supports Ability of Novel Selective PDE4D Inhibitor, BPN14770, to Improve Memory and Cognition
BPN14770 is a highly selective inhibitor of PDE4D, which regulates brain signaling pathways involved in the early and late stages of memory formation.
Tetra Discovery Partners Release: Company Appoints Richard Erwin As Vice President, Clinical Operations
Tetra Discovery Partners Announces Positive Results From Phase 1 Studies Of Cognition Drug Candidate, BPN14770
Tetra Discovery Partners Advances Alzheimer's Treatment Candidate BPN14770 To Phase I Multiple Ascending Dose Trial
Tetra Discovery Partners Initiates Phase 1 Study Of BPN14770, Under Development For Treatment And Prevention Of Alzheimer's Disease
Tetra Discovery Partners To Collaborate With Broad Institute's Stanley Center For Psychiatric Research To Pursue Schizophrenia Therapeutics
Tetra Discovery Partners Reaches New $1 Million Strategic Funding Milestone With Grand Angels-Led Investment